These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1277 related items for PubMed ID: 23796283

  • 21. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S, Ansell J.
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function.
    Hernandez I, Smith KJ, Zhang Y.
    Thromb Res; 2017 Feb; 150():123-130. PubMed ID: 27771008
    [Abstract] [Full Text] [Related]

  • 26. Cost-effectiveness of apixaban compared to warfarin in the management of atrial fibrillation in Australia.
    Ademi Z, Pasupathi K, Liew D.
    Eur J Prev Cardiol; 2015 Mar; 22(3):344-53. PubMed ID: 24281250
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation.
    Pink J, Pirmohamed M, Lane S, Hughes DA.
    Clin Pharmacol Ther; 2014 Feb; 95(2):199-207. PubMed ID: 24067746
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Novel oral anticoagulants in secondary prevention of stroke.
    Diener HC, Easton JD, Hankey GJ, Hart RG.
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):131-9. PubMed ID: 23953901
    [Abstract] [Full Text] [Related]

  • 34. Cost-effectiveness of apixaban versus warfarin and aspirin in Sweden for stroke prevention in patients with atrial fibrillation.
    Lanitis T, Kongnakorn T, Jacobson L, De Geer A.
    Thromb Res; 2014 Aug; 134(2):278-87. PubMed ID: 24935675
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey.
    Pisters R, Nieuwlaat R, Lane DA, Crijns HJ, Lip GY.
    Thromb Haemost; 2013 Feb; 109(2):328-36. PubMed ID: 23179181
    [Abstract] [Full Text] [Related]

  • 38. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era.
    Contractor T, Levin V, Martinez MW, Marchlinski FE.
    Postgrad Med; 2013 Jan; 125(1):34-44. PubMed ID: 23391669
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 64.